Sclerosis drug developed by Genmab brings in USD 66m to Novartis during Q2

The launch of sclerosis treatment Kesimpta is continuing to go well for Novartis, which has exceeded its financial expectations for the second quarter of this year.

Photo: CHARLES PLATIAU/Reuters / X00217

During Q2, sclerosis treatment Kesimpta brought in USD 66m to Novartis, the company financial report released on Wednesday states.

Kesimpta is far from the biggest treatment in Novartis' portfolio - Cosentyx, a psoriasis treatment, took that title in Q2 - but is nonetheless a growing asset for the company.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs